Real-Time FDA Review Of Bezuclastinib Combo In GIST Might Change The Case For Investing In Cogent Biosciences (COGT)
Cogent Biosciences recently announced that the FDA agreed to review its New Drug Application for bezuclastinib plus sunitinib in previously […]






